LIVE: Reuters NEXT Newsmaker with Genentech CEO Ashley Magargee

Three-year tariff exemption secured

Genentech entered a voluntary agreement with the administration securing a three-year exemption on tariffs to prevent manufacturing and supply disruptions for life-saving treatments.

2026 seeks predictability

After a turbulent 2025, pharmaceutical companies are prioritizing policy stability to resume capital investment without fear of supply chain disruption.

Medicaid pricing adjustments

The company lowered medicine prices in the Medicaid program to improve access for vulnerable populations while negotiating broader trade terms.

Middlemen capture 50% of drug costs

The US uniquely directs 50 cents of every drug dollar to PBMs, insurers, and distributors rather than manufacturers, creating a tipping point for congressional action.

Employer-led $70M savings model

Genentech implemented a modular PBM and evidence-based formulary for employees, projecting $70 million in savings by replacing opaque rebates with transparent clinical evidence criteria.

Congressional scrutiny increases

Congress is holding hearings and pursuing legislation to mandate PBM transparency and address why healthcare costs continue rising despite manufacturer price negotiations.

Record 80-molecule pipeline

Genentech currently has 80 molecules in development, the largest pipeline in its 50-year history, creating pressure on a healthcare system not designed to absorb this magnitude of innovation.

Medicare negotiation chilling effect

The Inflation Reduction Act's 9-year timeline for small molecules versus 13 years for biologics is driving venture capital and private equity away from small molecule R&D.

Direct-to-consumer expansion

The company piloted direct sales for flu medication and plans to expand the model to obesity and cardiovascular therapies to bypass pharmacy access bottlenecks and lower costs.

AI lab-in-the-loop strategy

Genentech is deploying AI to transform drug discovery and improve the industry's challenging economics: 10-15 year timelines, $2 billion costs, and high failure rates.

Obesity portfolio focus

Development prioritizes combination therapies, improved tolerability for maintenance therapy, and affordable options to address high patient dropout rates in anti-obesity treatments.

Shift toward curative treatments

R&D increasingly focuses on medicines that provide cures or halt disease progression rather than indefinite chronic management, benefiting both patient outcomes and system costs.